Physician profile
Brian G Smith
NPI 1952385817
$3,448.69
in general payments reported to CMS, 2019-2025
36 companies · $679 in 2025
The $679 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $221 · 2021: $159 · 2022: $495 · 2023: $741 · 2024: $564 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.81 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $624.30 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $291.86 | 2019-2025 | Xtandi |
| Dendreon Pharmaceuticals LLC | $276.24 | 2019-2025 | Provenge |
| Urogen Pharma, INC. | $208.36 | 2022-2025 | Jelmyto |
| Abbvie INC. | $172.92 | 2019-2025 | Botox, Lupron Depot |
| 180 Medical, INC. | $168.98 | 2019-2025 | Speedicath, Cure Catheter |
| Teleflex LLC | $142.31 | 2022-2025 | Barrigel, Urolift |
| Pfizer INC. | $134.02 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $133.48 | 2019-2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $122.63 | 2019-2024 | Upsylon, Advantage System |
| Medtronic, INC. | $118.06 | 2021-2024 | Aps |
| Stryker Corporation | $84.51 | 2019-2023 | Fluid Management System |
| Axonics, INC. | $83.52 | 2023-2024 | Bulkamid, Axonics |
| Ambu INC. | $70.01 | 2024 | |
| Olympus America INC. | $69.47 | 2022-2025 | Itind System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $64.81 | 2019 | |
| Allergan, INC. | $64.36 | 2020-2022 | |
| Procept Biorobotics Corporation | $62.30 | 2022-2025 | Aquabeam Robotic System |
| Neotract INC. | $59.89 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $50.45 | 2023-2025 | Gemtesa, Orgovyx |
| Progenics Pharmaceuticals, INC. | $49.18 | 2023 | Pylarify |
| Vertex Pharmaceuticals Incorporated | $48.52 | 2025 | |
| Convatec INC. | $41.24 | 2023 | |
| Becton, Dickinson and Company | $40.89 | 2024 | Bard Urinary Drainage Bag |
| Endo USA, INC. | $39.22 | 2024-2025 | Xiaflex |
| Tolmar Pharmaceuticals, INC. | $37.22 | 2020-2022 | |
| Myovant Sciences INC. | $30.56 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $24.65 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.14 | 2022 | |
| Calyxo, INC. | $18.94 | 2025 | Cvac Aspiration System |
| Laborie Medical Technologies Corp. | $18.18 | 2023 | |
| Antares Pharma, INC. | $16.52 | 2020 | |
| Urovant Sciences INC | $15.65 | 2022 | |
| Organon LLC | $15.35 | 2025 | |
| Myriad Genetic Laboratories, INC. | $15.09 | 2025 | Prolaris |
| Immunitybio, INC. | $14.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.